Actively Recruiting
Multi-Center PAMPA Study
Led by NYU Langone Health · Updated on 2026-03-30
176
Participants Needed
5
Research Sites
350 weeks
Total Duration
On this page
Sponsors
N
NYU Langone Health
Lead Sponsor
J
Janssen Scientific Affairs, LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of the proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an intervention that targets one of these pivotal molecules (i.e., Guselkumab) will: 1. Diminish MSKPDUS findings at 24 weeks, and 2. Significantly reduce or prevent the emergence of synovio-enthesial phenotype at year 2.
CONDITIONS
Official Title
Multi-Center PAMPA Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years old or older
- Male or female participants
- Psoriasis diagnosis by dermatologist for at least 2 years (at least 30% of participants)
- Willing and able to provide informed consent
- Meet high-risk psoriasis criteria: psoriasis duration over 2 years, body surface area affected greater than 3%, and positive musculoskeletal power Doppler ultrasound findings with RM-PsASon score over 3.36
You will not qualify if you...
- Evidence of inflammatory joint pain, enthesitis, or dactylitis on exam
- Current use of systemic immunosuppressive medications or any biologic therapy
- Rheumatoid arthritis seropositivity with mid to high RF/ACPA titers
- Active malignancy
- History of symptomatic polyarticular osteoarthritis or other joint diseases that impair assessment for psoriatic arthritis development
- Conditions prohibiting guselkumab use including active infection or untreated latent tuberculosis
- Known hypersensitivity to guselkumab or study agent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
2
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
3
University of Rochester Medical Center (URMC)
Rochester, New York, United States, 14623
Actively Recruiting
4
Memorial University
St. John's, Newfoundland and Labrador, Canada, A1C 5B8
Actively Recruiting
5
Women's College Research Institute, University of Toronto
Toronto, Ontario, Canada, M5S 1B2
Actively Recruiting
Research Team
J
Jose Scher, MD
CONTACT
S
Stephanie Eichman
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here